Navigation Links
Common cancer gene sends death order to tiny killer

Scientists at Johns Hopkins have discovered one way the p53 gene does what it's known for—stopping the colon cancer cells. Their report will be published in the June 8 issue of Molecular Cell.

The research team identified a tiny bit of genetic code, a microRNA called miR-34a that participates in p53's uncanny ability to kill cells likely to become malignant because of damaged genes in their nuclei. MicroRNAs are small chains of ribonucleic acid (RNA) made by the same machinery that produces other types of RNA in the cell, such as the messenger RNAs that carry the instructions to make proteins. Once produced, microRNAs stick to messenger RNAs and, like crumpled paper jammed in a copy machine, prevent proteins from being made.

Josh Mendell, M.D., Ph.D., an assistant professor in the McKusick-Nathans Institute of Genetic Medicine, suspected that p53 activates microRNAs like miR-34a because a number of studies have demonstrated that these tiny RNA molecules are frequently abnormal in cancer cells.

"P53 is one of the most commonly mutated genes in human cancers," says Mendell. "And there is now a great deal of evidence that microRNAs themselves can act to either promote cancer or to stop cancer spread."

To test their idea, the team first chemically damaged the DNA of two sets of colon cancer cells, one missing p53 and the other containing healthy p53. They then looked for any of the 500 known human microRNAs that are activated only in cells containing p53.

It turned out that the miR-34a gene is turned on by p53, and in fact, experiments demonstrated that p53 binds directly to the genetic material near miR-34a to promote its activation.

Concluding that p53 controls miR-34a, they next teamed up with Charlie Lowenstein, M.D., and his colleagues in Hopkins's department of medicine to put miR-34a into colon cancer cells. Doing this killed cells that contained p53, but fewer were killed in cells lacking p53, furthe r suggesting that this microRNA gets its kill orders from p53.

When researchers examined pancreatic cancer cells known to contain damaged or missing p53, they found that those cells had limited or zero miR-34a.

"With no p53 gene or miR-34a to stem tumor development, there's no brake in pancreatic cells and uncontrolled growth leads to cancer," says Anirban Maitra, M.B.B.S., associate professor of pathology, oncology and genetic medicine.

Mendell and his team are looking for missing miR-34a in other cancers. If it's a widespread phenomenon, the work could lead to treatments that aim to restore the missing microRNA to cancer cells.


'"/>

Source:Johns Hopkins Medical Institutions


Related biology news :

1. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
2. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
3. Men Estimate Mens Risks Of Common Disorders Higher Than Women Do, And Vice Versa
4. Use of Antibiotics for Acne May Increase Risk of Common Illness
5. Common viruses may cause cancer
6. Common alternative treatment for liver disease is found to be ineffective
7. Common molecular signature identified in solid tumors
8. Common bacteria pirate natural mechanism to get inside cells
9. Commonly used antidepressants may also affect human immune system
10. Common practices at petting zoos put visitors at risk
11. Common enzyme is a key player in DNA repair

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/2/2018)... ... August 02, 2018 , ... RxS LLC (“RxS”), a ... today announced that Mark Jara, principal of the organization, has been named to ... industry. Individuals named to PharmaVOICE 100 are leaders who drive the industry forward ...
(Date:8/1/2018)... ... August 01, 2018 , ... Clinical ... LPN’s, MA's and Administrative staff. , This full day course is an interactive ... course will expose your staff to regenerative medicine procedures and processing techniques, and ...
(Date:7/31/2018)... ... 31, 2018 , ... Lifecycle Biotechnologies, a leading life science ... this role, Mr. Muzek will lead the company-wide industrial strategic business development efforts ... , With over 20 years in business development, Mr. Muzek previously served as ...
Breaking Biology News(10 mins):
(Date:8/17/2018)... ... August 17, 2018 , ... VANCOUVER, British Columbia, Canada, August ... pleased to announce the release of the Russian translation of Best Practices: Recommendations ... 2018, is a practice-changing publication aimed at advancing the science of biobanking to ...
(Date:8/14/2018)... , ... August 14, 2018 , ... ... impetus at the 11th Congress of the Chinese Association of Orthopaedic Surgeons (CAOS) ... Fule Science & Technology Development , Beijing, and Invibio Biomaterial Solutions ...
(Date:8/9/2018)... ... 2018 , ... ActX introduces GenoACT(sm), a Genetic Clinical Decision ... talented scientific team that includes geneticists, PharmD’s, genetic counselors, and physicians aided by ... medical impact of a patient’s genetic variants , 2. Educational information for clinicians, ...
(Date:8/9/2018)... ... 09, 2018 , ... MedEvolve, Inc. , a national ... software and services for physician practices, announced today the company’s bookings for second ... record quarters in Q2 and Q3 last year, the company has exceeded those ...
Breaking Biology Technology: